Abstract

Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.

Is this guidance up to date?

We reviewed the evidence in December 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.

Guidance development process

How we develop NICE technology appraisal guidance